# TP53-mutated (p53-abnormal)

Source: https://onco.cc/terms/tp53-mutated/  
OnCo record `tp53-mutated` (Term). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Loss of the p53 'guardian of the genome', the most commonly mutated gene in cancer. In blood cancers and several solid tumours a TP53 mutation marks the highest-risk group, resistant to chemotherapy and hard to treat.

## Summary

TP53 is mutated in about half of all cancers and in almost all high-grade serous ovarian and small-cell lung cancers. Where it is variable it defines risk: TP53-mutated AML and MDS (especially multi-hit) have median survivals under a year and are excluded from many trials; del(17p)/TP53 CLL is treated with BTK inhibitors rather than chemoimmunotherapy; p53-abnormal endometrial cancer (by immunohistochemistry) is the aggressive molecular class that benefits from chemotherapy and trastuzumab if HER2-positive; TP53 and RB1 co-loss in prostate and lung adenocarcinoma predicts neuroendocrine transformation. Restoring p53 (eprenetapopt, MDM2 inhibitors for wild-type tumours) has so far disappointed.

## Fields

- Kind: Term
- Last checked: 2026-09-09
- Also known as: TP53-mutated; TP53-mutant; TP53 mutation; TP53 mutations; TP53 loss; TP53-altered; p53abn; p53-abnormal; p53 abnormal; p53-mutant; mutant p53; TP53/RB1; TP53 and RB1; multi-hit TP53

## Sources

- Wikipedia: https://en.wikipedia.org/wiki/P53
- Wikipedia: https://en.wikipedia.org/wiki/P53

## Connected records

- terms: [AML with myelodysplasia-related gene mutations (AML-MR)](https://onco.cc/terms/aml-myelodysplasia-related/), [Cytogenetics and karyotype](https://onco.cc/terms/cytogenetics/), [del(5q) (5q- syndrome and lenalidomide response)](https://onco.cc/terms/del5q/), [FOXO1 fusion status and IRS group (rhabdomyosarcoma)](https://onco.cc/terms/foxo1-fusion-status/), [IPSS-R and IPSS-M (myelodysplastic syndrome risk scores)](https://onco.cc/terms/ipss-m-ipss-r/), [Li-Fraumeni syndrome (germline TP53)](https://onco.cc/terms/li-fraumeni/), [Medulloblastoma molecular groups (WNT, SHH, group 3, group 4)](https://onco.cc/terms/medulloblastoma-molecular-groups/), [MIPI (Mantle Cell Lymphoma International Prognostic Index)](https://onco.cc/terms/mipi/), [No specific molecular profile (NSMP) endometrial cancer](https://onco.cc/terms/nsmp/), [POLE ultramutation (POLEmut)](https://onco.cc/terms/pole-ultramutation/), [Wild-type (WT)](https://onco.cc/terms/wild-type/), [Wilms tumour risk markers (anaplasia, 1p/16q loss, 1q gain, SIOP and COG risk groups)](https://onco.cc/terms/wilms-risk-markers/)
- cancers: [Acute myeloid leukaemia](https://onco.cc/cancers/aml/), [Chronic lymphocytic leukaemia](https://onco.cc/cancers/cll/), [Chronic lymphocytic leukaemia, first treatment](https://onco.cc/cancers/cll-treatment-naive/), [Endometrial cancer](https://onco.cc/cancers/endometrial/), [Higher-risk myelodysplastic syndromes](https://onco.cc/cancers/mds-higher-risk/), [Ovarian cancer](https://onco.cc/cancers/ovarian/), [Plasma cell leukaemia](https://onco.cc/cancers/plasma-cell-leukaemia/), [Richter transformation of chronic lymphocytic leukaemia](https://onco.cc/cancers/richter-transformation-cll/), [Secondary and therapy-related acute myeloid leukaemia](https://onco.cc/cancers/aml-secondary/)
- fronts: [Diagnostics & Biomarkers](https://onco.cc/fronts/diagnostics/)
- targets: [MDM2](https://onco.cc/targets/mdm2/), [TP53](https://onco.cc/targets/tp53/)
- key papers: [Hollstein 1991: p53 mutations in human cancers](https://onco.cc/key-papers/paper-hollstein-p53-mutations-science-1991/), [Levine 1997: p53, the cellular gatekeeper for growth and division](https://onco.cc/key-papers/paper-levine-p53-gatekeeper-cell-1997/), [Vogelstein, Lane and Levine 2000: surfing the p53 network](https://onco.cc/key-papers/paper-vogelstein-surfing-p53-network-nature-2000/)
- biomarkers: [TP53 mutation and del(17p)](https://onco.cc/biomarkers/tp53-del17p/)

---
JSON: https://onco.cc/api/v1/entities/tp53-mutated.json